Liposomes in the treatment of XXXX .

@entity1 @entity801 @entity2379 @entity234 @entity2348 @entity281 @entity364 @entity379 @entity3069 @entity35 @entity791
The use of liposomes in the treatment of severe @entity281 is under investigation. Classical liposomes which localize in cells of the mononuclear phagocyte system (MPS) can be exploited in two ways. First for targeting of macrophage modulators such as muramyl peptides or @entity379 , to stimulate the cells of the MPS to maximal blood clearance capacity. This enhanced nonspecific anti-infectious resistance is important as in immunocompromised @entity1 micro-organisms frequently appear in the blood from a @entity281 . Secondly, classical liposomes are successfully used as carriers of antibiotics in experimental intracellular parasitic-, @entity364 in MPS tissues. Based on these data extensive studies in @entity1 with severe @entity364 have demonstrated successful treatment with liposomal or lipid-complexed @entity2379 . More recently, liposomal @entity2379 appeared to be effective in @entity1 with @entity234 . For the treatment of @entity3069 complex infection in @entity791 @entity1 the efficacy of liposomal @entity801 is under investigation. With respect to @entity281 in non-MPS tissues the applicability of Stealth liposomes characterized by long circulation half-lives is under investigation. Substantial localization of these liposomes in infected lung tissue of @entity35 was demonstrated. Preliminary data in experimental @entity2348 showed superior efficacy of antibiotic encapsulated in Stealth liposomes.
